165 related articles for article (PubMed ID: 29121427)
1. Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
Tarumi Y; Mori T; Matsushima H; Kokabu T; Tsuchiya H; Kitawaki J
J Obstet Gynaecol Res; 2018 Feb; 44(2):347-351. PubMed ID: 29121427
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Liu B; An R; Yu J
J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
[TBL] [Abstract][Full Text] [Related]
3. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
Chen WC; Qiu JT; Lai CH; Huang HJ; Lin CT; Chen MY; Chou HH; Huang KG; Chang TC
PLoS One; 2017; 12(5):e0175703. PubMed ID: 28467466
[TBL] [Abstract][Full Text] [Related]
5. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
Chappell NP; Miller CR; Fielden AD; Barnett JC
J Oncol Pract; 2016 Jul; 12(7):e775-83. PubMed ID: 27246689
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
7. Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine.
Komiyama S; Kugimiya T; Takeya C; Takahashi R; Kubushiro K
J Obstet Gynaecol Res; 2018 Jul; 44(7):1330-1334. PubMed ID: 29767464
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Bruckner HW; Gurell D; Hirschfeld A
Anticancer Res; 2018 Jan; 38(1):547-552. PubMed ID: 29277822
[TBL] [Abstract][Full Text] [Related]
9. Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
Suminokura J; Miyamoto M; Yoshikawa T; Kouta H; Kikuchi Y; Hada T; Ishibashi H; Ito T; Iwahashi H; Kakimoto S; Suzuki R; Matsuura H; Kishimoto N; Takano M
BMC Cancer; 2022 Feb; 22(1):176. PubMed ID: 35172766
[TBL] [Abstract][Full Text] [Related]
10. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Takasaki K; Miyamoto M; Takano M; Soyama H; Aoyama T; Matsuura H; Kato K; Sakamoto T; Kuwahara M; Iwahashi H; Ishibashi H; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 May; 81(5):809-814. PubMed ID: 29500481
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
Kingnate C; Charoenkwan K; Kumfu S; Apaijai N; Jaiwongkam T; Khunamornpong S; Chattipakorn N; Chattipakorn SC
Biochem Pharmacol; 2021 Jun; 188():114587. PubMed ID: 33932471
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
Chikazawa K; Netsu S; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
[TBL] [Abstract][Full Text] [Related]
13. [Two cases of recurrent invasive mucinous adenocarcinoma of the lung showing marked responses to platinum-based chemotherapyregimens with pemetrexed and bevacizumab].
Koma Y; Nakashima N; Koyama M; Goto K; Yokota N; Kimura K; Matsumoto Y; Yoshida C; Matsuoka H; Masuya D; Yoshimatsu H; Suzuki Y
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1525-8. PubMed ID: 24231707
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; de Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E
J Clin Oncol; 2014 May; 32(13):1309-16. PubMed ID: 24687829
[TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; Marrelli D; Roviello F; Bianco V; Francini E
Future Oncol; 2015 Sep; 11(18):2563-74. PubMed ID: 26314701
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Myelodysplastic Syndrome Developed during Chemotherapy for Postoperative Recurrent Ovarian Cancer That Progressed to Acute Myeloid Leukemia].
Abe R; Murakami M; Okajima S; Suruga M; Nagatsuji M; Kawanishi M; Tokuyama O; Yamane T; Kawamura N
Gan To Kagaku Ryoho; 2023 Jul; 50(7):821-824. PubMed ID: 37496229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
